Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
- 12 October 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 100 (15), 1593-1601
- https://doi.org/10.1161/01.cir.100.15.1593
Abstract
Background —Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH) for management of unstable angina/non–Q-wave myocardial infarction (UA/NQMI). Methods and Results —Patients (n=3910) with UA/NQMI were randomized to intravenous UFH for ≥3 days followed by subcutaneous placebo injections or uninterrupted antithrombin therapy with enoxaparin during both the acute phase (initial 30 mg intravenous bolus followed by injections of 1.0 mg/kg every 12 hours) and outpatient phase (injections every 12 hours of 40 mg for patients weighing P =0.048) and by 43 days in 19.7% of the UFH group and 17.3% of the enoxaparin group (OR 0.85; 95% CI 0.72 to 1.00; P =0.048). During the first 72 hours and also throughout the entire initial hospitalization, there was no difference in the rate of major hemorrhage in the treatment groups. During the outpatient phase, major hemorrhage occurred in 1.5% of the group treated with placebo and 2.9% of the group treated with enoxaparin ( P =0.021). Conclusions —Enoxaparin is superior to UFH for reducing a composite of death and serious cardiac ischemic events during the acute management of UA/NQMI patients without causing a significant increase in the rate of major hemorrhage. No further relative decrease in events occurred with outpatient enoxaparin treatment, but there was an increase in the rate of major hemorrhage.This publication has 17 references indexed in Scilit:
- Failure to achieve optimal anticoagulation with commonly used heparin regimens; a review of GUSTO IIJournal of the American College of Cardiology, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaThe New England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionThe New England Journal of Medicine, 1998
- Low-Molecular-Weight HeparinsThe New England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseThe New England Journal of Medicine, 1997
- Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11AJournal of the American College of Cardiology, 1997
- Intracoronary stenting in the treatment of acute or threatened closure in angiographically small coronary arteries (<3.0 mm) complicating percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1995
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery diseaseThe Lancet, 1990
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaThe New England Journal of Medicine, 1988